home / stock / mtsr / mtsr quote
Last: | $29.24 |
---|---|
Change Percent: | 5.52% |
Open: | $29.5 |
Close: | $27.71 |
High: | $30.67 |
Low: | $28.33 |
Volume: | 561,868 |
Last Trade Date Time: | 06/20/2025 11:39:41 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$29.24 | $29.5 | $27.71 | $30.67 | $28.33 | 561,868 | 06-20-2025 |
$27.71 | $25.91 | $27.71 | $27.99 | $24.83 | 1,412,712 | 06-19-2025 |
$27.71 | $25.91 | $27.71 | $27.99 | $24.83 | 1,412,712 | 06-18-2025 |
$25.38 | $26.3 | $25.38 | $26.58 | $24.13 | 1,132,789 | 06-17-2025 |
$26.87 | $31.34 | $26.87 | $31.34 | $26.56 | 1,018,221 | 06-16-2025 |
$29.38 | $33.39 | $29.38 | $34.75 | $29.24 | 811,609 | 06-13-2025 |
$34.58 | $33.19 | $34.58 | $34.94 | $32.25 | 482,632 | 06-12-2025 |
$33.06 | $35.42 | $33.06 | $35.71 | $32.55 | 852,854 | 06-11-2025 |
$35.1 | $32.35 | $35.1 | $37.9864 | $32.01 | 2,974,080 | 06-10-2025 |
$30.39 | $31.6 | $30.39 | $35.19 | $28.445 | 3,182,106 | 06-09-2025 |
$27.49 | $29.24 | $27.49 | $29.55 | $26.78 | 391,897 | 06-06-2025 |
$28.67 | $28.21 | $28.67 | $29.73 | $28 | 558,134 | 06-05-2025 |
$28.58 | $29.05 | $28.58 | $29.33 | $27.88 | 617,689 | 06-04-2025 |
$29.35 | $28.4 | $29.35 | $30.33 | $28.03 | 495,560 | 06-03-2025 |
$28.12 | $26.99 | $28.12 | $29.2 | $26.12 | 617,536 | 06-02-2025 |
$26.72 | $27.2 | $26.72 | $27.405 | $25.47 | 919,892 | 05-30-2025 |
$27.59 | $28.49 | $27.59 | $28.595 | $27 | 778,036 | 05-29-2025 |
$28.01 | $27.85 | $28.01 | $28.775 | $27.15 | 420,881 | 05-28-2025 |
$27.83 | $27.99 | $27.83 | $29.78 | $27.8 | 854,603 | 05-27-2025 |
$27.3 | $27.48 | $28.045 | $28.02 | $26.5003 | 1,098,296 | 05-26-2025 |
News, Short Squeeze, Breakout and More Instantly...
Metsera Inc. Company Name:
MTSR Stock Symbol:
NASDAQ Market:
5.52% G/L:
$29.24 Last:
561,868 Volume:
$29.50 Open:
$27.71 Close:
Metsera Inc. Website:
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Ch...
Metsera Inc. (MTSR) is expected to report for Q1 2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chi...